Navigation Links
Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement
Date:4/30/2008

nce. In 2004, he was named Chief Scientific Officer of the Year by IBC Conferences.

Dr. Dohlsten, 49, previously was Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with major programs in seven therapeutic areas including respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and CNS. In addition, he was a member of the corporate management team responsible for reviewing all worldwide development projects and licensing opportunities. Prior to joining Boehringer Ingelheim, Dr. Dohlsten spent more than 15 years in various leadership roles in pharmaceutical research including positions with AstraZeneca and Pharmacia & Upjohn.

Dr. Dohlsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.

"We look forward to Dr. Dohlsten's leadership as we work together to continue our success at Wyeth Research," says Bernard Poussot. "His experience with industry in a broad range of therapeutic areas, and his vision going forward, match well with our scientific objectives. We know Mikael's global experience and perspective will be an inspiration to Wyeth's outstanding research teams."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
7. Wyeth Announces Executive Change in Finance Organization
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technologies are used to develop, manufacture and sell ... chemical, biopharmaceutical and industrial enzyme industries, announced today ... Form 10 with the U.S. Securities and Exchange ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form 10 ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... and NEW YORK, Sept. 17 ,Microbia, Inc. ... ), today announced,that they have entered into ... to,co-develop and co-market Microbia,s first-in-class compound linaclotide.,Linaclotide ... of,constipation-predominant irritable bowel syndrome (IBS-C), chronic,constipation (CC), ...
... Experience in Pulmonary and Infectious Disease ... ... a,clinical stage biopharmaceutical company focused on developing products to,overcome issues of ... Company,s Chief Medical Officer. Dr. Loutit,joins Mpex from InterMune, Inc. where ...
... Sept. 17 Kyphon Inc.,(Nasdaq: KYPH ... clearance from the,Federal Trade Commission (FTC) and ... Improvements Act of 1976 (as amended) with,respect ... assets,and associated intellectual property rights of Disc-O-Tech ...
Cached Biology Technology:Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 2Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 3Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 4Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 5Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 2Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 3Federal Trade Commission Clears Kyphon's Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech 2
(Date:8/19/2014)... parts of the world, leprosy and tuberculosis live ... of leprosy per year, with nearly all of ... available century-old vaccine Bacille Calmette-Guerin, or BCG, provides ... so a more potent vaccine is needed to ... a stronger weapon against both diseases., In a ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Despite ongoing public health efforts, E. coli ... sickness and death throughout the world. But the ... published today in the scientific journal Nature , researchers ... discovered a molecule,s previously unknown role in fighting off ...
... of North Carolina scientists have uncovered a new strategy ... and chronic obstructive pulmonary disorder better clear the thick ... to life-threatening infections. In a new report appearing online ... researchers show that the "SPLUNC1" protein and its derivative ...
... July 13, 2012, Shenzhen, China - An international team, ... Academy of Science, and BGI, the world,s largest genomics ... salt cress ( Thellungiella salsuginea ), a wild salt-tolerant ... tool for exploring mechanisms of adaptive evolution and sheds ...
Cached Biology News:La Jolla institute identifies critical cell in fighting E. coli infection 2La Jolla institute identifies critical cell in fighting E. coli infection 3New proteins to clear the airways in cystic fibrosis and COPD 2Salt cress genome yields new clues to salt tolerance 2
Green Standard is fluorescein....
Red Standard is sodium salt of resorufin....
Human Jagged 2 Biotinylated Affinity Purified PAb...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: